The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...

Bullish option flow detected in BridgeBio (BBIO) Pharma with 2,983 calls trading, 1.0x expected, and implied vol increasing over 2 points to 132.22%. Dec-24 30 calls and Dec-24 35 calls are the ...

BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, were published as an original research ...

Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $45 from $44 and keeps an Outperform rating on the shares. The firm continues to like the setup for the company, with upcoming ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price raised by Scotiabank from $45.00 to $48.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector ...

BridgeBio (BBIO) Pharma presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was ...

Below is Validea's guru fundamental report for BRIDGEBIO PHARMA INC (BBIO). Of the 22 guru strategies we follow, BBIO rates highest using our Contrarian Investor model based on the published ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...